What Does a Cardio-oncology Service Offer to the Oncologist and the Haematologist?
- PMID: 33832839
- DOI: 10.1016/j.clon.2021.03.012
What Does a Cardio-oncology Service Offer to the Oncologist and the Haematologist?
Abstract
Cardio-oncology is an emerging subspecialty arising from the need for multidisciplinary collaboration to address the increasing prominence of cardiovascular disease (CVD) among cancer patients. This overview outlines the case for establishing cardio-oncology services and defines the ways in which these services benefit cancer patients. The primary objective of cardio-oncology is to manage CVDs in order to allow cancer patients to complete the best cancer treatments safely and with minimal interruption. In the decades since the first discovery of heart failure induced by anthracycline chemotherapy, both cardiovascular and oncological science have advanced considerably. Cardio-oncology services aim to bring together expertise from these two fast moving fields in order to provide optimal evidence-based care for cancer patients with CVDs. Here we discuss the basis of cardio-oncology services by presenting their rationale and key components, as well as their essential roles in education, training and research. At each stage of the cancer care pathway, a cardio-oncology service can add value by ensuring cancer patients have timely access to specialist care backed up by cutting edge diagnostic tools and treatment options, as well as holistic supports. We highlight areas of recent and upcoming developments in the field that are likely to change established clinical practice. Improved cardiac imaging modalities can detect chemotherapy-related cardiac dysfunction earlier and are also essential for the prompt diagnosis of an expanding range of cardiovascular effects complicating newer cancer therapeutics, such as immune checkpoint inhibitors and other targeted therapies. Modern cancer therapy has dramatically improved cancer survival and as such CVD is becoming one of the principal determinants of overall outcome for cancer patients. A dedicated cardio-oncology service can facilitate the optimisation of cardiovascular treatment and enable the completion of cancer therapy. A multidisciplinary collaborative approach is key to achieving these objectives.
Keywords: Cardio-oncology; cardiotoxicity; chemotherapy; immunotherapy; multidisciplinary; service.
Copyright © 2021 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
Similar articles
-
Current Knowledge and Implementation of Therapeutic Strategies in Cardio-Oncology: A National Physician-Based Survey.Am J Ther. 2025 May-Jun 01;32(3):e223-e233. doi: 10.1097/MJT.0000000000001970. Am J Ther. 2025. PMID: 40338679
-
Rationale for setting up a cardio-oncology unit: our experience at Mayo Clinic.Cardiooncology. 2016 Apr 19;2(1):5. doi: 10.1186/s40959-016-0014-2. Cardiooncology. 2016. PMID: 33530144 Free PMC article. Review.
-
[The Cardio-Oncology Guideline - A Comprehensive Approach to Managing Cardiovascular Risks in Cancer Patients].Dtsch Med Wochenschr. 2024 Jun;149(12):719-723. doi: 10.1055/a-2104-6363. Epub 2024 May 23. Dtsch Med Wochenschr. 2024. PMID: 38781996 Review. German.
-
Cardio-oncology: rationale, aims and future directions.Curr Opin Support Palliat Care. 2021 Jun 1;15(2):134-140. doi: 10.1097/SPC.0000000000000544. Curr Opin Support Palliat Care. 2021. PMID: 33605633 Review.
-
Interactions between cardiology and oncology drugs in precision cardio-oncology.Clin Sci (Lond). 2021 Jun 11;135(11):1333-1351. doi: 10.1042/CS20200309. Clin Sci (Lond). 2021. PMID: 34076246 Free PMC article. Review.
Cited by
-
Cardio-Oncology and Heart Failure: a Scientific Statement From the Heart Failure Society of America.J Card Fail. 2025 Feb;31(2):415-455. doi: 10.1016/j.cardfail.2024.08.045. Epub 2024 Oct 15. J Card Fail. 2025. PMID: 39419165 Review.
-
Risk and Management of Patients with Cancer and Heart Disease.Cardiol Ther. 2023 Jun;12(2):227-241. doi: 10.1007/s40119-023-00305-w. Epub 2023 Feb 9. Cardiol Ther. 2023. PMID: 36757637 Free PMC article. Review.
-
The United Kingdom's First Cardio-Oncology Service: A Decade of Growth and Evolution.JACC CardioOncol. 2024 Feb 6;6(2):310-312. doi: 10.1016/j.jaccao.2023.12.003. eCollection 2024 Apr. JACC CardioOncol. 2024. PMID: 38774020 Free PMC article. No abstract available.
-
Investigating the effect of cancer medication in the development of Takotsubo cardiomyopathy.Am J Cardiovasc Dis. 2024 Aug 25;14(4):196-207. doi: 10.62347/STFL9135. eCollection 2024. Am J Cardiovasc Dis. 2024. PMID: 39309116 Free PMC article. Review.
-
Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do.Cancers (Basel). 2022 Nov 2;14(21):5403. doi: 10.3390/cancers14215403. Cancers (Basel). 2022. PMID: 36358830 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical